ATE297735T1 - Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff - Google Patents
Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoffInfo
- Publication number
- ATE297735T1 ATE297735T1 AT01910421T AT01910421T ATE297735T1 AT E297735 T1 ATE297735 T1 AT E297735T1 AT 01910421 T AT01910421 T AT 01910421T AT 01910421 T AT01910421 T AT 01910421T AT E297735 T1 ATE297735 T1 AT E297735T1
- Authority
- AT
- Austria
- Prior art keywords
- antimuscarine
- inhibitor
- act
- new active
- active combination
- Prior art date
Links
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 title 1
- 229930182837 (R)-adrenaline Natural products 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 229960005139 epinephrine Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18479000P | 2000-02-24 | 2000-02-24 | |
| PCT/US2001/003698 WO2001062236A2 (en) | 2000-02-24 | 2001-01-23 | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE297735T1 true ATE297735T1 (de) | 2005-07-15 |
Family
ID=22678338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01910421T ATE297735T1 (de) | 2000-02-24 | 2001-02-23 | Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20020010216A1 (de) |
| EP (1) | EP1257277B1 (de) |
| JP (1) | JP2003523382A (de) |
| CN (2) | CN1660435A (de) |
| AR (1) | AR027956A1 (de) |
| AT (1) | ATE297735T1 (de) |
| AU (1) | AU781254B2 (de) |
| CA (1) | CA2399442A1 (de) |
| DE (1) | DE60111500T2 (de) |
| DK (1) | DK1257277T3 (de) |
| ES (1) | ES2241802T3 (de) |
| MX (1) | MXPA02008183A (de) |
| NZ (1) | NZ520975A (de) |
| PE (1) | PE20011306A1 (de) |
| PT (1) | PT1257277E (de) |
| WO (1) | WO2001062236A2 (de) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE305788T1 (de) | 1999-07-01 | 2005-10-15 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetin zur behandlung von inkontinenz |
| SI1196172T1 (sl) * | 1999-07-01 | 2006-06-30 | Pharmacia & Upjohn Co Llc | (S,S)-reboksetin za zdravljenje kronicne bolecine |
| BR0211522A (pt) * | 2001-07-31 | 2004-09-14 | Upjohn Co | Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| DE10146275A1 (de) * | 2001-09-18 | 2003-04-24 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| US20050014843A1 (en) * | 2001-11-30 | 2005-01-20 | Allen Albert John | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders |
| WO2003068211A1 (en) * | 2002-02-12 | 2003-08-21 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
| PT1485078E (pt) * | 2002-03-15 | 2013-01-14 | Cypress Bioscience Inc | Milnacipran para o tratamento do síndrome do intestino irritável |
| US7754242B2 (en) * | 2002-03-20 | 2010-07-13 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
| EP1485344A1 (de) * | 2002-03-28 | 2004-12-15 | Synthon B.V. | Venlafaxinbesylat |
| WO2003082805A1 (en) * | 2002-03-28 | 2003-10-09 | Synthon B.V. | Low water-soluble venlafaxine salts |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| MY142204A (en) * | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
| WO2004019892A2 (en) * | 2002-08-30 | 2004-03-11 | Watson Pharmaceuticals, Inc. | Drug delivery system for treating urinary incontinence |
| JP2006504795A (ja) * | 2002-10-03 | 2006-02-09 | サイプレス バイオサイエンス， インコーポレイテッド | 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬 |
| US6974820B2 (en) * | 2002-11-06 | 2005-12-13 | Bridge Pharma, Inc. | Methods for treating urinary incontinence and other disorders using trospium |
| EP1424079A1 (de) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| WO2004058353A2 (en) * | 2002-12-24 | 2004-07-15 | Paradigm Therapeutics Ltd. | Therapeutic use of selective noradrenaline reuptake inhibitors |
| US6943193B1 (en) * | 2003-01-21 | 2005-09-13 | Jordan A. Altabet | Method for treating sexual dysfunction |
| FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| NZ541733A (en) | 2003-02-14 | 2009-03-31 | Pf Medicament | Use of the enantiomer (1S,2R) of milnacipran for the preparation of a medicament |
| CA2519379A1 (en) * | 2003-04-04 | 2004-10-21 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| EP1622450A4 (de) * | 2003-04-25 | 2009-11-18 | Endo Pharmaceuticals Solutions | Verfahren zur förderung des durchschlafens durch verabreichung von trospiumchlorid |
| WO2005020976A2 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| DE602004030931D1 (de) | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| UA88477C2 (ru) * | 2004-08-13 | 2009-10-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение |
| ME01316B (me) * | 2004-08-13 | 2013-12-20 | Boehringer Ingelheim Int | Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so |
| EP1858515A2 (de) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzungen zur behandlung und/oder vorbeugung von mit angstzuständen verbundenen erkrankungen |
| WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US20060287347A1 (en) * | 2005-06-21 | 2006-12-21 | Aberg A K G | Methods for treating smooth muscle disorders using trospium |
| US7390816B2 (en) * | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| US20070004766A1 (en) * | 2005-07-01 | 2007-01-04 | Aberg A K G | Methods for relaxation of smooth muscle contractions using Trospium |
| CA2617546C (en) | 2005-08-03 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of obesity |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| US20090098202A1 (en) * | 2006-02-10 | 2009-04-16 | Boehringer Ingelheim International Gmbh | Extended Release Formulation |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| BRPI0712039A2 (pt) * | 2006-05-09 | 2011-12-20 | Boehringer Ingelheim Int | uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa |
| WO2008000760A1 (en) | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
| CA2657043A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
| US8304601B2 (en) * | 2007-01-23 | 2012-11-06 | Keiko Fujikawa | Mouse model for eye disease |
| US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| PE20091188A1 (es) * | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
| IT1392333B1 (it) * | 2008-12-16 | 2012-02-28 | Giofarma S R L | Preparazione farmaceutica per il trattamento di patologie depressive, contenente una proteina con elevato rapporto triptofano/lnaa |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| ES2742728T3 (es) | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| JP2013510176A (ja) | 2009-11-06 | 2013-03-21 | ピエール ファーブル メディカモン | （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態 |
| ES2552166T3 (es) | 2010-04-12 | 2015-11-26 | Supernus Pharmaceuticals, Inc. | Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas |
| US20120289744A1 (en) | 2010-11-03 | 2012-11-15 | Arch Pharmalabs Limited | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts |
| CN119185558A (zh) * | 2017-04-28 | 2024-12-27 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CN111670050A (zh) | 2018-01-30 | 2020-09-15 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| WO2019245975A1 (en) | 2018-06-17 | 2019-12-26 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| PT3856182T (pt) | 2018-09-28 | 2026-03-10 | Karuna Therapeutics Inc | Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| CA3117766A1 (en) * | 2018-10-31 | 2020-05-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| ES3049086T3 (en) | 2019-02-08 | 2025-12-12 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| US12616702B2 (en) | 2019-12-03 | 2026-05-05 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| EP4146621A1 (de) | 2020-05-05 | 2023-03-15 | Apnimed, Inc. (Delaware) | Polymorphe formen von (r)-oxybutyninhydrochlorid |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2002492A1 (en) * | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
| GB9517883D0 (en) * | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
-
2001
- 2001-01-23 WO PCT/US2001/003698 patent/WO2001062236A2/en not_active Ceased
- 2001-01-23 CN CN2005100039430A patent/CN1660435A/zh active Pending
- 2001-01-23 JP JP2001561303A patent/JP2003523382A/ja active Pending
- 2001-01-23 NZ NZ520975A patent/NZ520975A/en unknown
- 2001-01-23 MX MXPA02008183A patent/MXPA02008183A/es active IP Right Grant
- 2001-01-23 CN CN01804031A patent/CN1396829A/zh active Pending
- 2001-01-23 PT PT01910421T patent/PT1257277E/pt unknown
- 2001-02-16 PE PE2001000175A patent/PE20011306A1/es not_active Application Discontinuation
- 2001-02-23 DK DK01910421T patent/DK1257277T3/da active
- 2001-02-23 AR ARP010100838A patent/AR027956A1/es unknown
- 2001-02-23 ES ES01910421T patent/ES2241802T3/es not_active Expired - Lifetime
- 2001-02-23 AU AU38028/01A patent/AU781254B2/en not_active Ceased
- 2001-02-23 CA CA002399442A patent/CA2399442A1/en not_active Abandoned
- 2001-02-23 EP EP01910421A patent/EP1257277B1/de not_active Expired - Lifetime
- 2001-02-23 US US09/792,718 patent/US20020010216A1/en not_active Abandoned
- 2001-02-23 DE DE60111500T patent/DE60111500T2/de not_active Expired - Fee Related
- 2001-02-23 AT AT01910421T patent/ATE297735T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AR027956A1 (es) | 2003-04-16 |
| ES2241802T3 (es) | 2005-11-01 |
| WO2001062236A3 (en) | 2002-03-07 |
| CN1396829A (zh) | 2003-02-12 |
| EP1257277A2 (de) | 2002-11-20 |
| DK1257277T3 (da) | 2005-09-12 |
| DE60111500D1 (de) | 2005-07-21 |
| JP2003523382A (ja) | 2003-08-05 |
| NZ520975A (en) | 2004-03-26 |
| AU3802801A (en) | 2001-09-03 |
| US20020010216A1 (en) | 2002-01-24 |
| PE20011306A1 (es) | 2001-12-29 |
| MXPA02008183A (es) | 2002-11-29 |
| EP1257277B1 (de) | 2005-06-15 |
| CN1660435A (zh) | 2005-08-31 |
| PT1257277E (pt) | 2005-09-30 |
| WO2001062236A2 (en) | 2001-08-30 |
| AU781254B2 (en) | 2005-05-12 |
| DE60111500T2 (de) | 2006-05-18 |
| CA2399442A1 (en) | 2001-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60111500D1 (de) | Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff | |
| NO20024528L (no) | Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen | |
| ID30590A (id) | Celana sekali pakai jenis-celana pendek | |
| DK1282611T3 (da) | Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer | |
| PT1326853E (pt) | Novos tiadiazoles e oxadiazoles e sua utilizacao como inibidores da fosfodiesterase-7 | |
| DK1305301T3 (da) | Alpha-acyl- og alpha-heteroatomsubstituerede benzenacetamidglucokinase-aktivatorer | |
| EP1298180A4 (de) | Hydrophobe und lipophobe zusammensetzung | |
| DE60003148D1 (de) | Bestimmung der Cachezeit | |
| NO20023616D0 (no) | Ny anvendelse | |
| PT1296564E (pt) | Concentrado liquido para granizado e metodo para o fabrico do mesmo | |
| EE200200604A (et) | Dipeptidüüli peptidaasi IV inhibiitorid | |
| EP1248642A4 (de) | Peptidomimetischer inhibitor von vegf sowie vegf-c und -d | |
| NO992492D0 (no) | Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer | |
| NO20005265L (no) | Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser | |
| DE60126814D1 (de) | Inhalation von stickoxid | |
| DE60143864D1 (de) | Positive chemisch verstärkte Resistzusammensetzung | |
| DE60106968D1 (de) | Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren | |
| FI20001715L (fi) | Rankoihin liittyvõt jõrjestelyt ja menetelmõt | |
| MXPA03003796A (es) | Procedimiento y dispositivos de aplicacion por vertido. | |
| DE60117938D1 (de) | Vorspannen von Bauteilen | |
| AR028068A1 (es) | Nuevos derivados de 1,1-dioxotiocromano y su uso como inhibidores de trombina | |
| DE50203882D1 (de) | Mittel, die die apoptose bei an der wundheilung beteiligten zellen inhibieren | |
| FI20011069L (fi) | Uusia vetoelimien käyttöjä puurakentamisessa | |
| AR028122A1 (es) | Nuevos compuestos aminotiolésteres, composiciones farmacéuticas y cosméticas que los contienen y utilizaciones | |
| EE200300507A (et) | HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1257277 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |